Author: Tuccori, Marco; Ferraro, Sara; Convertino, Irma; Cappello, Emiliano; Valdiserra, Giulia; Blandizzi, Corrado; Maggi, Fabrizio; Focosi, Daniele
Title: Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline Cord-id: glmp1uz1 Document date: 2020_12_15
ID: glmp1uz1
Snippet: Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 pandemic, early signals of efficacy from convalescent plasma therapy have encouraged research and development of anti-SARS-CoV-2 mAbs. While many candidates are in preclinical development, we focus here on anti-SARS-CoV-2 neutralizing mAbs (or mAb cocktails) that represent the late-stage clinical pipeline, i.e., those
Document: Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 pandemic, early signals of efficacy from convalescent plasma therapy have encouraged research and development of anti-SARS-CoV-2 mAbs. While many candidates are in preclinical development, we focus here on anti-SARS-CoV-2 neutralizing mAbs (or mAb cocktails) that represent the late-stage clinical pipeline, i.e., those currently in Phase 2 or Phase 3 clinical trials. We describe the structure, mechanism of action, and ongoing trials for VIR-7831, LY-CoV555, LY-CoV016, BGB-DXP593, REGN-COV2, and CT-P59. We speculate also on the next generation of these mAbs.
Search related documents:
Co phrase search for related documents- acceptable risk benefit ratio show and action mechanism: 1
- action mechanism and acute lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- action mechanism and additional patient: 1
- action mechanism and additive effect: 1, 2, 3, 4
- action mechanism and load reduction: 1, 2
- acute lung injury and ade antibody dependent enhancement: 1
- acute lung injury and administered dosage: 1
- acute lung injury and admission rate: 1, 2
- additional patient and admission rate: 1
- ade antibody dependent enhancement and admission rate: 1
Co phrase search for related documents, hyperlinks ordered by date